Target intelligence / Profile preview

CDC42 effector protein 5 (CDC42EP5)

Target: CDC42EP5
Molecular classification: Other (Borg family), Cytoskeletal regulator, CDC42 effector protein

Overview

CDC42 effector protein 5 (CDC42EP5) is a binder and downstream effector of CDC42, belonging to the Borg (binder of Rho GTPases) family of proteins. It contains a CRIB (Cdc42/Rac interactive binding) domain that enables binding to active CDC42, thereby modulating its cytoskeleton-organizing functions. CDC42EP5 participates in the regulation of actin filaments, septin organization, cell shape, and the formation of pseudopodia and lamellipodia in fibroblasts. This protein can inhibit c-Jun N-terminal kinase (JNK) independently of CDC42 binding and may participate in the formation of filamentous structures with actin or septins, thereby influencing cell migration, morphology, and possibly cancer-related changes. CDC42EP5 does not act as a classical receptor, enzyme, or ion channel, and there are currently no approved drugs or biomarker applications related to it.

Other names: Borg3CEP5Cdc42 effector protein 5Binder of Rho GTPases 3

Biological functions

Cytoskeletal remodelingCell shape regulationInduction of actin filament assemblySeptin organizationPseudopodia and lamellipodium formation

Disease associations

Cancer (implicated via cytoskeletal and migratory changes; evidence is emerging, not yet fully established as a disease target)Other (may play roles in development, neuronal regulation, and cell migration)

Safety considerations

no safety concerns or therapeutic challenges directly related to targeting CDC42EP5; however, manipulation of cytoskeletal elements like Borg proteins can broadly impact cell division, migration, and structural integrity, which are critical for normal cell function

Beyond the preview

Go deeper on CDC42 effector protein 5 (CDC42EP5).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

Drug candidates
Developers
Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

Trial design
Status
Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

Programs
Modalities
Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

Publications
Sources
Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

Patents
Assignees
Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

Biology
Development news
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CDC42 effector protein 5 (CDC42EP5).

Explore the full profile